Angiogenesis inhibition by proteins, peptides and small molecules: Clinical application;Angiogenese-hemmung durch proteine, peptide und «small molecules»: Klinischer einsatz

Onkologie

Volumn 28, Issue SUPPL. 4, 2005, Pages 29-34

  Jayson, Gordon ^a   Armand, Jean Pierre ^b   Berdel, Wolfgang E ^c  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CILENGITIDE; CISPLATIN; ENDOSTATIN; FLUOROURACIL; FOLINIC ACID; IMATINIB; IRINOTECAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LM 609; NAVELBINE; OXALIPLATIN; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VATALANIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ARTICLE; COLORECTAL CARCINOMA; HUMAN; NEUTROPENIA; THROMBOCYTOPENIA; CANCER INVASION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; MORTALITY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; SURVIVAL RATE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SURVIVAL RATE;

EID: 33644834243     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088826     Document Type: Article

References (19)

1. Yang JC, Haworth L, Sherry RM, et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434.
2. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
3. Willett CG, Boucher Y, Di Tomaso E, et al.: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147.
4. Giantonio BJ, Catalano PJ, Meropol NJ, et al.: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc ASCO 2005;23:16S (suppl) abstr 2.
5. Johnson DH, Fehrenbacher L, Novotny WF, et al.: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22(11):2184-2191.
6. Sandler AB, Gray R, Brahmer J, et al.: Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC 704865) in patients with advanced non-sqamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) trial - E4599. Proc ASCO 2005;23:16S (suppl) abstr LBA4.
7. Miller KD et al.: ECOG E2100 study. Presented at ASCO Annual Meeting 2005, Orlando, Florida.
8. Posey JA, Ng TC, Yang B et al.: A phase I study of anti-kinase insert domain-containing receptor antibody, IMC 1C11, in patients with liver metastasis from colorectal carcinoma. Clin Cancer Res 2003;9:1323-1332.
9. Holash J, Davis S, Papadopoulos N et al.: VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99(17):11393-11398.
10. Dupont J, Rothenberg ML, Spriggs DR et al.: Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors. Proc ASCO 2005;23:16S (suppl) abstr 3029.
11. Eskens FA, Dumez H, Hoekstra R, et al.: Phase I and pharmacokinetic study of continous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumors. Eur J Cancer 2003;39:917-926.
12. Sun Y, Wang J, Liu X, et al.: Results of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients. Proc ASCO 2005;23:16S (suppl) abstr 7138.
13. Escudier B, Szczylik C, Eisen T, et al.: Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc ASCO 2005;23:16S (suppl) abstr LBA4510.
14. Wood JM, Bold G, Buchdunger E, et al.: PTK787/ZK 222584, a novel and potent inihibitor for VEGF receptor tyrosine kinases, impairs VEGF-induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178-2189.
15. Thomas AL, Morgan B, Drevs J et al.: Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin Oncol. 2003;30 (suppl 6):32-38.
16. Hecht JR, Trarbach T, Jaeger E, et al.: A randomized, double-blind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluoruracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1) Proc Am Soc Clin Oncol 2005;23:16S (suppl) abstr LBA3.
17. Mendel DB, Laird AD, Xin X, et al.: In vivo antitumor acticity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-deriven growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-337.
18. Motzer RJ, Rini BI, Michaelson MD et al.: SU011248, a novel tyrosinekinase inhibitor, shows antitumor actvity in second-line therapy for patients with metastatic renal cell carcinoma: Reults of a phase 2 trial. Proc Am Soc Clin Oncol 2004;23;381 abstr 4500.
19. Demetri GD, van Oosterom AT, Blackstein M, et al.: Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST. Proc Am Soc Clin Oncol 2005;23:16S (suppl) abstr 4000.